How Will AstraZeneca's Acquisition Transform Oncology Resear

AstraZeneca has acquired Boston-based Modella AI to accelerate oncology drug research. The deal integrates Modella's foundation models and AI agents into AstraZeneca's global oncology R&D pipeline. Announced on January 13 at JPMorgan Healthcare Conference, this marks the first acquisition of an AI firm by a major pharmaceutical company.

Oncology generates large amounts of multimodal data daily, histopathology slides, genomic sequencing, and clinical records. Traditional analysis relies on manual pathologist review. Modella AI trains foundation models across these data types simultaneously, then deploys AI agents that refine predictions with streaming patient data.

The acquisition targets "quantitative pathology," AI analysis of biopsies for protein expression and clinical correlation. "Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer. Computers now quantify expression across thousands of cells per slide and nominate therapeutic targets at machine speed.​

In an interview at the J.P. Morgan Healthcare Conference, AstraZeneca ‍ Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.

From Collaboration to Ownership

The companies have been collaborating since July 2025. The acquisition brings data, algorithms, and talent in-house, eliminating SaaS fees and IP risks.

Modella's founders bring institutional expertise. Co-founder Faisal Mahmood, Mass General Brigham professor, specializes in pathology AI. CEO Jill Stefanelli built the agentic platform. Their models train on de-identified oncology patient data, capturing rare edge cases synthetic datasets miss.

Jorge Reis-Filho, AstraZeneca's Chief of AI for Science Innovation, emphasized "targeted therapeutics along with diagnostics." Modella enables joint biomarker-therapy discovery, identifying responders, explaining mechanisms, nominating companion diagnostics simultaneously.

AstraZeneca's oncology portfolio generated $12B in H1 2025 alone, led by Tagrisso ($3.5B) and Enhertu ($1.3B). Modella AI's foundation models process multimodal pathology data to support biomarker discovery across AstraZeneca's oncology pipeline.

"Modella AI was built at the intersection of pathology, clinical data, and advanced generative AI to tackle some of the hardest problems in oncology," Mahmood said. "Integrating our foundation models directly into AstraZeneca's research ecosystem will help translate methodological advances into real-world impact faster."

The JPMorgan Healthcare Conference saw multiple high-profile announcements. Nvidia and Eli Lilly revealed their $1 billion co-innovation lab, Schrodinger integrated Lilly's TuneLab platform, and Revvity announced similar access for biotechs. Most competitors pursue licensing partnerships with shared intellectual property arrangements. AstraZeneca chose acquisition.

Partnerships create vendor dependencies and divided economics. Acquisitions deliver full control over model evolution, training data, and deployment infrastructure. AstraZeneca gains immediate access to frontier pathology foundation models plus the engineering talent to customize them for specific oncology challenges across its global portfolio.​

AstraZeneca said the acquisition of Modella AI is intended to support its oncology research and development efforts by strengthening its internal capabilities in pathology and biomarker discovery.

Modella AI develops artificial intelligence models designed to analyze pathology and clinical data used in cancer research. AstraZeneca said integrating the technology in-house will allow its research teams to apply AI tools more closely across ongoing oncology programs.

Company executives said the acquisition aligns with AstraZeneca’s broader strategy to link diagnostics and targeted therapies in oncology. AstraZeneca has not disclosed specific technical deployment details or timelines but said the acquisition will allow it to continue developing and adapting AI models internally as part of its global oncology research organization.

"AstraZeneca is transforming its drug discovery and clinical development through the deployment of innovative and impactful AI solutions," said Jorge Reis-Filho. "The acquisition of Modella AI provides state-of-the-art frontier pathology foundation models and AI agents that will continue to enable the development of targeted therapeutics along with diagnostics in our oncology portfolio."